Molnupiravir for treating COVID-19 (TA1056)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 26 February 2026Published: 16 April 2025
Nirmatrelvir plus ritonavir and tocilizumab for treating COVID-19 (TA878)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 26 February 2026Published: 29 March 2023
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 May 2024
Tixagevimab plus cilgavimab for preventing COVID-19 (TA900)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 June 2023